Under the 2022 ACR/EULAR classification criteria [10,16], patients with MPO-ANCA positivity, asthma, mononeuritis multiplex, migratory pulmonary infiltrates, and biopsy-proven small- to medium-sized vasculitis with extravascular eosinophil infiltration but without eosinophilia exceeding 1000/mm3 would no longer be classified as having EGPA, as was possible under previous criteria, but would instead be reclassified as having MPA. Here, MPO is linked to asthma.